Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells
Authors:
- Rosaliana LibroRLRosaliana Libro
- Francesca DiomedeFDFrancesca Diomede
- Domenico SciontiDSDomenico Scionti
- Adriano PiattelliAPAdriano Piattelli
- Gianpaolo GrassiGGGianpaolo Grassi
- Federica PollastroFPFederica Pollastro
- Placido BramantiPBPlacido Bramanti
- Emanuela MazzonEMEmanuela Mazzon
- Oriana TrubianiOTOriana Trubiani
Open Access
- 23 December 2016
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (1) , 26
Abstract
Mesenchymal stem cells (MSCs) have emerged as a promising tool for the treatment of several neurodegenerative disorders, including Alzheimer’s disease (AD). The main neuropathological hallmarks of AD are senile plaques, composed of amyloid beta (Aβ), and neurofibrillary tangles, formed by hyperphosphorylated tau. However, current therapies for AD have shown limited efficacy. In this study, we evaluated whether pre-treatment with cannabidiol (CBD), at 5 μM concentration, modulated the transcriptional profile of MSCs derived from gingiva (GMSCs) in order to improve their therapeutic potential, by performing a transcriptomic analysis by the next-generation sequencing (NGS) platform. By comparing the expression profiles between GMSCs treated with CBD (CBD-GMSCs) and control GMSCs (CTR-GMSCs), we found that CBD led to the downregulation of genes linked to AD, including genes coding for the kinases responsible of tau phosphorylation and for the secretases involved in Aβ generation. In parallel, immunocytochemistry analysis has shown that CBD inhibited the expression of GSK3β, a central player in AD pathogenesis, by promoting PI3K/Akt signalling. In order to understand through which receptor CBD exerted these effects, we have performed pre-treatments with receptor antagonists for the cannabinoid receptors (SR141716A and AM630) or for the vanilloid receptor 1 (TRPVI). Here, we have proved that TRPV1 was able to mediate the modulatory effect of CBD on the PI3K/Akt/GSK3β axis. In conclusion, we have found that pre-treatment with CBD prevented the expression of proteins potentially involved in tau phosphorylation and Aβ production in GMSCs. Therefore, we suggested that GMSCs preconditioned with CBD possess a molecular profile that might be more beneficial for the treatment of AD.Keywords
This publication has 53 references indexed in Scilit:
- Anandamide Reduces Intracellular Ca2+ Concentration through Suppression of Na+/Ca2+ Exchanger Current in Rat Cardiac MyocytesPLOS ONE, 2013
- Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammationNeurobiology of Aging, 2012
- Heat Shock Protein 70 Prevents both Tau Aggregation and the Inhibitory Effects of Preexisting Tau Aggregates on Fast Axonal TransportBiochemistry, 2011
- Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSCCell Communication and Signaling, 2011
- CB1 Cannabinoid Receptors Increase Neuronal Precursor Proliferation through AKT/Glycogen Synthase Kinase-3β/β-Catenin SignalingJournal of Biological Chemistry, 2010
- An Overview of APP Processing Enzymes and ProductsNeuroMolecular Medicine, 2009
- The GSK3 hypothesis of Alzheimer’s diseaseJournal of Neurochemistry, 2007
- Phosphoinositide 3-Kinase Binds to TRPV1 and Mediates NGF-stimulated TRPV1 Trafficking to the Plasma MembraneJournal of General Physiology, 2006
- Molecular Chaperones and Protein Quality ControlCell, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006